197 related articles for article (PubMed ID: 35794607)
1. Valuing EQ-5D-Y: the current state of play.
Devlin N; Pan T; Kreimeier S; Verstraete J; Stolk E; Rand K; Herdman M
Health Qual Life Outcomes; 2022 Jul; 20(1):105. PubMed ID: 35794607
[TBL] [Abstract][Full Text] [Related]
2. Accounting for Unobservable Preference Heterogeneity and Evaluating Alternative Anchoring Approaches to Estimate Country-Specific EQ-5D-Y Value Sets: A Case Study Using Spanish Preference Data.
Ramos-Goñi JM; Oppe M; Estévez-Carrillo A; Rivero-Arias O;
Value Health; 2022 May; 25(5):835-843. PubMed ID: 35500952
[TBL] [Abstract][Full Text] [Related]
3. Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective.
Kreimeier S; Oppe M; Ramos-Goñi JM; Cole A; Devlin N; Herdman M; Mulhern B; Shah KK; Stolk E; Rivero-Arias O; Greiner W
Value Health; 2018 Nov; 21(11):1291-1298. PubMed ID: 30442276
[TBL] [Abstract][Full Text] [Related]
4. EQ-5D-Y as a Health-Related Quality of Life Instrument for Children and Adolescents: The Instrument's Characteristics, Development, Current Use, and Challenges of Developing Its Value Set.
Kreimeier S; Greiner W
Value Health; 2019 Jan; 22(1):31-37. PubMed ID: 30661631
[TBL] [Abstract][Full Text] [Related]
5. Efficient Designs for Valuation Studies That Use Time Tradeoff (TTO) Tasks to Map Latent Utilities from Discrete Choice Experiments to the Interval Scale: Selection of Health States for TTO Tasks.
Che M; Pullenayegum E
Med Decis Making; 2023 Apr; 43(3):387-396. PubMed ID: 36866604
[TBL] [Abstract][Full Text] [Related]
6. Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values.
Fitriana TS; Roudijk B; Purba FD; Busschbach JJV; Stolk E
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):157-167. PubMed ID: 36348155
[TBL] [Abstract][Full Text] [Related]
7. Preparatory study for the revaluation of the EQ-5D tariff: methodology report.
Mulhern B; Bansback N; Brazier J; Buckingham K; Cairns J; Devlin N; Dolan P; Hole AR; Kavetsos G; Longworth L; Rowen D; Tsuchiya A
Health Technol Assess; 2014 Feb; 18(12):vii-xxvi, 1-191. PubMed ID: 24568945
[TBL] [Abstract][Full Text] [Related]
8. Think of the Children: A Discussion of the Rationale for and Implications of the Perspective Used for EQ-5D-Y Health State Valuation.
Lipman SA; Reckers-Droog VT; Kreimeier S
Value Health; 2021 Jul; 24(7):976-982. PubMed ID: 34243841
[TBL] [Abstract][Full Text] [Related]
9. International Valuation Protocol for the EQ-5D-Y-3L.
Ramos-Goñi JM; Oppe M; Stolk E; Shah K; Kreimeier S; Rivero-Arias O; Devlin N
Pharmacoeconomics; 2020 Jul; 38(7):653-663. PubMed ID: 32297224
[TBL] [Abstract][Full Text] [Related]
10. Estimating an EQ-5D-Y-3L Value Set for China.
Yang Z; Jiang J; Wang P; Jin X; Wu J; Fang Y; Feng D; Xi X; Li S; Jing M; Zheng B; Huang W; Luo N
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):147-155. PubMed ID: 36396878
[TBL] [Abstract][Full Text] [Related]
11. Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan.
Shiroiwa T; Ikeda S; Noto S; Fukuda T; Stolk E
Med Decis Making; 2021 Jul; 41(5):597-606. PubMed ID: 33754886
[TBL] [Abstract][Full Text] [Related]
12. Valuing health-related quality of life among the Indian population: a protocol for the Development of an EQ-5D Value set for India using an Extended design (DEVINE) Study.
Jyani G; Prinja S; Kar SS; Trivedi M; Patro B; Purba F; Pala S; Raman S; Sharma A; Jain S; Kaur M
BMJ Open; 2020 Nov; 10(11):e039517. PubMed ID: 33444194
[TBL] [Abstract][Full Text] [Related]
13. Does Changing the Age of a Child to be Considered in 3-Level Version of EQ-5D-Y Discrete Choice Experiment-Based Valuation Studies Affect Health Preferences?
Ramos-Goñi JM; Estévez-Carrillo A; Rivero-Arias O; Rowen D; Mott D; Shah K; Oppe M
Value Health; 2022 Jul; 25(7):1196-1204. PubMed ID: 35379562
[TBL] [Abstract][Full Text] [Related]
14. Understanding Canadian stakeholders' views on measuring and valuing health for children and adolescents: a qualitative study.
Xie F; Xie S; Pullenayegum E; Ohinmaa A
Qual Life Res; 2024 May; 33(5):1415-1422. PubMed ID: 38438665
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan.
Shiroiwa T; Ikeda S; Noto S; Igarashi A; Fukuda T; Saito S; Shimozuma K
Value Health; 2016; 19(5):648-54. PubMed ID: 27565282
[TBL] [Abstract][Full Text] [Related]
16. EQ-5D-Y Value Set for Germany.
Kreimeier S; Mott D; Ludwig K; Greiner W;
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):217-229. PubMed ID: 35604633
[TBL] [Abstract][Full Text] [Related]
17. An exploration of methods for obtaining 0 = dead anchors for latent scale EQ-5D-Y values.
Shah KK; Ramos-Goñi JM; Kreimeier S; Devlin NJ
Eur J Health Econ; 2020 Sep; 21(7):1091-1103. PubMed ID: 32506281
[TBL] [Abstract][Full Text] [Related]
18. Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries.
Bernert S; Fernández A; Haro JM; König HH; Alonso J; Vilagut G; Sevilla-Dedieu C; de Graaf R; Matschinger H; Heider D; Angermeyer MC;
Value Health; 2009; 12(5):750-8. PubMed ID: 19490564
[TBL] [Abstract][Full Text] [Related]
19. Using Both Time Tradeoff and Discrete Choice Experiments in Valuing the EQ-5D: Impact of Model Misspecification on Value Sets.
Waudby-Smith I; Pickard AS; Xie F; Pullenayegum EM
Med Decis Making; 2020 May; 40(4):483-497. PubMed ID: 32517541
[No Abstract] [Full Text] [Related]
20. Value Set for the EQ-5D-Y-3L in Hungary.
Rencz F; Ruzsa G; Bató A; Yang Z; Finch AP; Brodszky V
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):205-215. PubMed ID: 36123448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]